|
|
|
|
||
This should brighten your day - says MNKD potential limitless!!!!"MannKind is the most prudent choice for investing in diabetes and
obesity because the company is medium sized. Now that MannKind has
command of the vast armies of Sanofi sales/marketing reps to deliver
Afrezza, a revolutionary diabetes treatment the world has yet to see,
the potential for MannKind is limitless." (emphasis added) |
return to message board, top of board |